Avalo Therapeutics AVTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 7.7×-14.9× | 8.1×-11.8× | 14.3×+12.9× | 12.4×+11.4× | 22.6×+22.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | 0×— | 0×— | —— | |
| Per Share | ||||||
| Book value per share | $3.40-70.9% | $6.20-65.1% | $6.54— | $9.66— | $11.66— | |
| Valuation | ||||||
| Market capitalization | $954.59M+1,783% | $329.31M+324% | $167.17M+81.4% | $53.6M+316% | $85.48M+390% | |
| Price / book | 13.8×+13.4× | 4×— | 1.8×— | 0.5×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's profit margins?
- Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
- Where do Avalo Therapeutics's ratios come from?
- Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
